![New First-in-Class Therapy for Chronic Graft-Versus-Host Disease Approved in Australia[1]](https://mma.prnewswire.com/media/1986460/Specialised_Therapeutics_Logo.jpg?p=facebook "New First-in-Class Therapy for Chronic Graft-Versus-Host Disease Approved in Australia[1]"){kind=logo}
NIKTIMVO® (axatilimab) approved by the Therapeutic Goods Administration (TGA) under Priority Review for the treatment of eligible Australian patients with chronic graft-versus-host disease[2] Australia becomes the first country to obtain Marketing Authorisation for NIKTIMVO since approval...
Hence then, the article about new first in class therapy for chronic graft versus host disease approved in australia 1 was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( New First-in-Class Therapy for Chronic Graft-Versus-Host Disease Approved in Australia[1] )
Also on site :
- OPEC+ makes first output decision after UAE exit – Reuters
- Meteorological alert: Temperature drop and unstable weather conditions across Egypt
- We Asked 7 Chefs for Their Favorite Frozen Meals and We're Obsessed With These Answers